United Capital Financial Advisers LLC Purchases New Stake in PerkinElmer, Inc. (NYSE:PKI)


Share on StockTwits

United Capital Financial Advisers LLC purchased a new stake in PerkinElmer, Inc. (NYSE:PKI) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 2,594 shares of the medical research company’s stock, valued at approximately $372,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Creative Planning boosted its holdings in PerkinElmer by 2.3% in the fourth quarter. Creative Planning now owns 4,648 shares of the medical research company’s stock valued at $667,000 after acquiring an additional 104 shares during the last quarter. Knowledge Leaders Capital LLC increased its stake in PerkinElmer by 1.4% in the fourth quarter. Knowledge Leaders Capital LLC now owns 8,274 shares of the medical research company’s stock valued at $1,187,000 after purchasing an additional 112 shares in the last quarter. Bailard Inc. increased its stake in PerkinElmer by 7.8% in the fourth quarter. Bailard Inc. now owns 1,833 shares of the medical research company’s stock valued at $263,000 after purchasing an additional 133 shares in the last quarter. Diversified Trust Co increased its stake in PerkinElmer by 7.4% in the fourth quarter. Diversified Trust Co now owns 1,952 shares of the medical research company’s stock valued at $280,000 after purchasing an additional 134 shares in the last quarter. Finally, Treasurer of the State of North Carolina increased its stake in PerkinElmer by 0.3% in the fourth quarter. Treasurer of the State of North Carolina now owns 42,660 shares of the medical research company’s stock valued at $6,122,000 after purchasing an additional 140 shares in the last quarter. Institutional investors and hedge funds own 89.44% of the company’s stock.

Shares of PerkinElmer stock opened at $130.18 on Thursday. The company has a market capitalization of $14.59 billion, a price-to-earnings ratio of 35.38, a PEG ratio of 0.99 and a beta of 1.19. The company has a quick ratio of 0.96, a current ratio of 1.35 and a debt-to-equity ratio of 0.46. PerkinElmer, Inc. has a 12-month low of $74.84 and a 12-month high of $162.70. The firm’s 50-day moving average price is $128.70 and its two-hundred day moving average price is $135.21.

PerkinElmer (NYSE:PKI) last posted its quarterly earnings results on Tuesday, February 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.01 by $0.95. PerkinElmer had a net margin of 12.74% and a return on equity of 21.57%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.22 billion. During the same period last year, the company posted $1.35 EPS. The firm’s quarterly revenue was up 68.2% compared to the same quarter last year. On average, sell-side analysts expect that PerkinElmer, Inc. will post 7.12 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 7th. Investors of record on Friday, April 16th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, April 15th. This represents a $0.28 annualized dividend and a yield of 0.22%. PerkinElmer’s dividend payout ratio is presently 6.83%.

In related news, insider Daniel R. Tereau sold 2,047 shares of PerkinElmer stock in a transaction that occurred on Monday, February 1st. The shares were sold at an average price of $147.07, for a total transaction of $301,052.29. Following the sale, the insider now directly owns 10,378 shares in the company, valued at approximately $1,526,292.46. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.62% of the stock is owned by company insiders.

Several brokerages have commented on PKI. Smith Barney Citigroup upped their target price on shares of PerkinElmer from $140.00 to $150.00 in a research note on Friday, December 11th. Citigroup increased their target price on shares of PerkinElmer from $150.00 to $155.00 in a report on Wednesday, February 3rd. Wells Fargo & Company upgraded shares of PerkinElmer from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $140.00 to $175.00 in a report on Thursday, January 7th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their target price on shares of PerkinElmer from $140.00 to $150.00 in a report on Friday, December 11th. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $133.93.

PerkinElmer Company Profile

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

Read More: What is a good rate of return for a mutual fund?

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.